AML Target Market Intelligence, ADC/Bispecific Clinical Progress, and High-Purity Reagents for Myeloid Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD33 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD33 ECD-Fc / ΔExon2 Mutant Protein High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD33 Products |
| Gene Delivery | CD33 Promise-ORF / Lentivirus Full-length ORF for stable AML cell line engineering. |
View CD33 Products |
| Benchmark Ab | Anti-CD33 (Gemtuzumab Biosimilar Sequence) Recombinant positive control for binding/internalization. |
View CD33 Products |
| Validator | CD33 siRNA Set For knockdown verification and specificity controls. |
View CD33 Products |
| Related Target: CD3E | CD3E (T-cell engaging) For bispecific (BiTE) development and T-cell activation assays. |
View CD3E Products |
| Related Target: CD123 (IL3RA) | CD123 (IL-3Rα) Synergistic AML target; co-expression with CD33 for dual-targeting strategies. |
View IL3RA Products |
| Related Target: CLEC12A (CLL-1) | CLL-1 (CLEC12A) Alternative myeloid target with superior stem cell sparing profile. |
View CLEC12A Products |
| Related Target: SIGLEC5 | Siglec-5 Close homology off-target liability; required for selectivity counter-screening. |
View SIGLEC5 Products |
| Related Target: FLT3 | FLT3 Key combination therapy pathway in AML; often co-mutated. |
View FLT3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Evaluation | Human/Cynomolgus/Mouse CD33 ortholog proteins available with >95% purity; sequence identity verified by mass spec. |
| Siglec Family Off-Target Liability | Homolog panel proteins (Siglec-5, -6, -14) strictly verified for selectivity screening. |
| Internalization Efficiency (ADC) | High-purity V-set/C2-set domain ECD-Fc preserves native glycosylation for accurate uptake assays. |
| Alternative Splicing Resistance | Wild-type vs Exon-2 deletion (ΔE2) mutant proteins for epitope mapping and escape variant detection. |
| Lack of Controls | Clinical Benchmark Antibodies (Gemtuzumab biosimilar) included for assay calibration. |
| False Positives | Validated siRNA included for target-specificity verification. |
Live CD33 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD33-targeted therapeutics is intensifying, with major players shifting focus from first-generation ADCs to next-generation modalities including T-cell engagers, site-specific conjugates, and combination regimens. As Gemtuzumab ozogamicin redefines its clinical niche in combination regimens (e.g., with hypomethylating agents or Venetoclax), the next wave of R&D is targeting resistance mechanisms (CD33 splice variants, especially ΔExon2) and dual-antigen strategies (CD33/CD123, CD33/CLL-1) to overcome leukemic stem cell heterogeneity and reduce myelosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Cleavable/Non-cleavable) | Pfizer (Mylotarg), Jazz Pharma/ImmunoGen, Daiichi Sankyo, Seattle Genetics | AML, sAML, MDS | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| Bispecific (T-cell Engager) | Amgen (AMG 330), Amphivena, J&J | Relapsed/Refractory AML | Heterodimer Validation & T-cell Activation (Need Cross-reactive Abs & species-matched proteins) |
| CAR-T/NK | University of Pennsylvania, Cartesian Therapeutics, Novartis | AML, BPDCN | Cell Surface Density Quantification & Killing Assays (Need Lentivirus stable lines) |
| Radioimmunotherapy | Actinium Pharma (Iomab-B) | R/R AML, MDS | Binding Affinity & Stability under physiological conditions |
| Small Molecule / Allosteric | Academic Consortia | Myeloid Malignancies | Selectivity Assay (Need CD33 del2 vs WT protein panel) |
Summary
To support robust CD33 drug discovery, TarMart provides a comprehensive toolkit including high-purity ECD-Fc proteins (wild-type and ΔExon2 mutant), lentiviral gene delivery, benchmark antibodies, validated siRNA, and a panel of Siglec family proteins for selectivity. These reagents address key assay challenges—internalization efficiency, splicing variant resistance, cross-species evaluation, and off-target liability—enabling streamlined development of ADCs, bispecifics, CAR-T, and other modalities.